Lipid Status During Combined Treatment in Prostate Cancer Patients-Reference-Cited by-同舟云学术

Lipid Status During Combined Treatment in Prostate Cancer Patients

Published:2019-09-27 Issue:5 Volume:13 Page:155798831987648
ISSN:1557-9883
Container-title:American Journal of Men's Health
language:en
Short-container-title:Am J Mens Health

Author:

Wolny-Rokicka Edyta¹²^ORCID,Tukiendorf Andrzej³,Wydmański Jerzy⁴,Ostrowska Małgorzata⁵,Zembroń-Łacny Agnieszka²

Affiliation:

1. Department of Radiotherapy, Multidisciplinary Hospital, Gorzow Wielkopolski, Poland

2. Faculty of Medicine and Health Sciences, University of Zielona Góra, Zielona Góra, Poland

3. Social Medicine Department, Medical University, Wrocław, Poland

4. Department of Radiotherapy, Centre of Oncology, Maria Skłodowska-Curie Memorial Institute, Branch in Gliwice, Poland

5. Department of Nephrology, Medical University Hospital of Karol Marcinkowski, Zielona Góra, Poland

Abstract

The aim of this study was to provide a specific review of current medical literature regarding the lipid profile during prostate carcinoma (PCa) treatment. The main aim was to analyze the results presented by different authors and to find a commonality in the changes occurring during the treatment—hormonotherapy. The levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol were measured before and after the follow-up treatment. The manuscripts reviewed came from the period between 2008 and 2016. The size of the studies ranged from 16 participants to 310. The mean age was from 65 to 74 years in all studies. The Q test was used to attain all lipid parameters and to specify heterogeneity ( p < .0001). After 12 months of androgen deprivation therapy (ADT), the patients had a significantly higher level serum TC and TG.

Publisher

SAGE Publications

Subject

Public Health, Environmental and Occupational Health,Health (social science)

Link

http://journals.sagepub.com/doi/pdf/10.1177/1557988319876488

Reference45 articles.

1. Prediagnostic Total and High-Density Lipoprotein Cholesterol and Risk of Cancer

2. Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes

3. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

4. Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis

5. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401;International Journal of Urology;2023-12-26

2. Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study;The Prostate;2023-03-20

3. Effects of Androgen Deprivation Therapy on Blood Lipids and Fasting Blood Glucose in Patients with Prostate Cancer;The Bulletin of Urooncology;2022-03-01

4. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC;Clinical and Translational Medicine;2022-02

5. ADVERSE EFFECTS OF ANDROGEN DEPRIVATION THERAPY ON PATIENTS WITH PROSTATE CANCER AND ITS EFFECT ON OVERALL SURVIVAL;The Japanese Journal of Urology;2021-04-20